Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2979)	6/29/2010 3:10:34 PM
From: mlkr	Respond to of 3722

OREX's reason to go higher: BOSTON (MarketWatch) -- Orexigen Therapeutics and Amylin Pharmaceuticals led drug stocks northward Monday, with shares of the two biotechs gaining on positive studies unveiled over the weekend at a meeting of the American Diabetes Association. The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x (DRG 276.18, -3.35, -1.20%) and the NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x (BTK 1,043, -31.37, -2.92%) both moved marginally higher to 280.49 and 1,085.28, respectively, after beginning the session in negative territory. Orexigen shares /quotes/comstock/15!orex/quotes/nls/orex (OREX 4.43, -0.47, -9.59%) shot up 14% to $4.73. Hot Stocks: Oil, gas stocks move lower Energy stocks in the S&P 500 Index fall, tracking crude prices lower. BP PLC shares are among the sector's few gainers as a tropical storm churning off Mexico's Yucatan Peninsula appears to be steering clear of the Gulf oil spill. MarketWatch's Alistair Barr reports. On Saturday, Orexigen presented positive data for its obesity treatment Contrave that showed the product lessened symptoms of depression and improved eating control in obese patients who suffered from major depression. An advisory panel of the U.S. Food and Drug Administration is expected to review Contrave's application on Dec. 7. The agency is scheduled to make a decision on whether to approve the product by Jan. 31, 2011. Shares of Amylin /quotes/comstock/15!amln/quotes/nls/amln (AMLN 18.92, -0.11, -0.58%) were up 2% at $19.60. At the ADA meeting, Amylin presented results from studies for its diabetes drugs Byetta and Symlin, and also its drug candidate Bydureon, which is currently awaiting FDA approval.

To: Jibacoa who wrote (2979)	7/26/2010 12:26:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

OREX is trying to rally after its recent setback.<g> The stock was up 10.34% and is still up 5.98% on volume >3/4 its ADV bigcharts.marketwatch.com The stock was hurt on July 15 from the FDA's panel decision on VVUS Qnexa, since OREX's Contrave had also reported last Yr. good results on its PIII for the treatment of obesity.<g> The ACTAY has been trimmed to $11.80 The stock has now a good amount of resistance at the $6 level, which is where I will still keep a TT.<g> bigcharts.marketwatch.com Bernard